Loading...
Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
Brodalumab is a novel fully human immunoglobulin G2 monoclonal antibody that antagonizes the interleukin (IL)-17 pathway by binding with high affinity to human IL-17RA. The role of IL-17A in the pathogenesis of psoriasis, as well as the remarkable effectiveness of IL-17 inhibitors in the treatment o...
Na minha lista:
| Udgivet i: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5511025/ https://ncbi.nlm.nih.gov/pubmed/28744098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S113683 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|